Cormorant Asset Management, LP Allakos Inc. Transaction History

Cormorant Asset Management, LP

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2021 Aug 16, 2021	SELL	$85.37 - $114.1 $2.13 Million - $2.85 Million	-25,000 Closed	0 $0
Q1 2021 May 17, 2021	SELL	$109.73 - $153.66 $2.74 Million - $3.84 Million	-25,000 Reduced 50.0%	25,000 $2.87 Million
Q4 2020 Feb 16, 2021	SELL	$79.58 - $152.45 $1.99 Million - $3.81 Million	-25,000 Reduced 33.33%	50,000 $7 Million
Q3 2020 Nov 16, 2020	SELL	$66.43 - $90.99 $8.14 Million - $11.1 Million	-122,515 Reduced 62.03%	75,000 $6.11 Million
Q2 2020 Aug 14, 2020	SELL	$44.04 - $80.69 $109,439 - $200,514	-2,485 Reduced 1.24%	197,515 $14.2 Million
Q1 2020 May 15, 2020	SELL	$44.49 - $93.39 $4.45 Million - $9.34 Million	-100,000 Reduced 33.33%	200,000 $8.9 Million
Q4 2019 Feb 14, 2020	SELL	$66.49 - $137.73 $9.58 Million - $19.8 Million	-144,100 Reduced 32.45%	300,000 $28.6 Million
Q3 2019 Nov 14, 2019	SELL	$31.0 - $89.73 $6.38 Million - $18.5 Million	-205,900 Reduced 31.68%	444,100 $34.9 Million
Q2 2019 Aug 14, 2019	SELL	$36.0 - $44.73 $3.6 Million - $4.47 Million	-100,000 Reduced 13.33%	650,000 $28.2 Million
Q1 2019 May 15, 2019	BUY	$33.79 - $51.99 $20.3 Million - $31.2 Million	600,000 Added 400.0%	750,000 $30.4 Million
Q4 2018 Feb 14, 2019	BUY	$31.59 - $62.65 $4.74 Million - $9.4 Million	150,000 New	150,000 $7.84 Million

64.7M

47.1K

Ticker ALLK
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 84,726,096
Market Cap $82.2M
Description
Allakos Inc., a clinical stage biopharmaceutical company, develops therapeutics that target immunomodulatory receptors present on immune effector cells in allergy, inflammatory, and proliferative diseases. The company's lead monoclonal antibody is lirentelimab (AK002), which is in a Phase III study for the treatment of eosinophilic gastritis and...

Get notified when there are updates to the investment portfolio of Cormorant Asset Management, LP, based on Form 13F filings with the SEC.

Stay updated on Cormorant Asset Management, LP with notifications on news.